15 Nov, 2009 in
News & Articles by
admin
|
Researchers conducted a study to look at a novel tumor suppressor, FUS1/TUSC2, as well as its relationship to malignant pleural mesothelioma, an aggressive form of cancer that attacks the lining surrounding the lungs. The study evaluated clinical specimens of malignant pleural mesothelioma for TUSC2 insufficiency at the mRNA level, the DNA level as well as the protein level. The link between asbestos exposure as well as TUSC2 expressed was evaluated by using reactive oxygen species (ROS) scavengers as well as asbestos-treated mesothelial cells. The results of the study determined that TUSC2 shows potential for immunotherapy in malignant pleural mesothelioma treatment. For the filled story, go to 7th Space Interactive. |